NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Doc, while the proneural population percentage would tend to go up with removal of mesenchymal, I lean towards the fact that no biopsy surgery for nGBM in the phase III trial could in turn decrease proneural (and neural) percentages-- although it's simply a hypothesis. Thus resulting in a fairly normal distribution, or perhaps even less proneurals.

I think the original thought was Optune would help proneurals, Rintega Classicals, ICT-107 neurals, and DCVax-L mesenchymal and some classical. In other words I think times have changed. If you look at the trial designs, it kind of looks like everyone was going to stay in their boudaries, but Rintega failed, ICT-107 is really very narrowly focused, Optune has not to my knowledge released a detailed subtype distribution amongst placebo/treatment from its registrational nGBM trial, and DCVax-L is apparently causing almost everyone to do better and live longer than expected across what one might infer are all subtypes.